Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 10/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | SCN1A | P35498 | 2/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 2/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dilazep SCHEMBL2597896 | 1.00 | SLC29A1 (1.00) | SLC29A1MEN1KMT2ASMN1; SMN2CYP2D6 | |
| Dilazep SCHEMBL220842 | 0.99 | SMN1; SMN2 (1.00) | SLC29A1MEN1KMT2ASMN1; SMN2CYP2D6 | |
| Dilazep SCHEMBL349239 | 0.99 | SMN1; SMN2 (1.00) | SLC29A1MEN1KMT2ASMN1; SMN2CYP2D6 | |
| Dilazep SCHEMBL9934077 | 0.97 | SMN1; SMN2 (0.98) | SLC29A1MEN1KMT2ASMN1; SMN2CYP2D6 | |
| Dilazep SCHEMBL15532226 | 0.97 | SLC29A1 (0.95) | SLC29A1MEN1KMT2ASMN1; SMN2CYP2D6 | |
| SCHEMBL27319577 | 0.93 | SLC29A1 (0.87) | SLC29A1MEN1KMT2ASMN1; SMN2CYP2D6 | |
| SCHEMBL2459734 | 0.91 | SLC29A1 (0.83) | SLC29A1MEN1KMT2ASMN1; SMN2CYP2D6 | |
| SCHEMBL27319054 | 0.91 | SLC29A1 (0.83) | SLC29A1MEN1KMT2ASMN1; SMN2CYP2D6 | |
| SCHEMBL8686213 | 0.88 | SLC29A1 (0.79) | SLC29A1MEN1KMT2ASMN1; SMN2CYP2D6 | |
| Dilazep SCHEMBL11130839 | 0.87 | SLC29A1 (0.77) | SLC29A1MEN1KMT2ASMN1; SMN2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4688 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12550885-B2 | Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells | UNIVERSITY OF CINCINNATI (US) | 2026-02-17 | — | — | US | claimed |
| WO-2025262072-A2 | NEURONAL DRUG SCREENING METHOD AND NEW APPLICATIONS FOR DILAZEP AND PENBUTOLOL | MIĘDZYNARODOWY INSTYTUT BIOLOGII MOLEKULARNEJ I KOMÓRKOWEJ (PL) | 2025-12-26 | — | — | WO | claimed |
| EP-4658278-A1 | SELECTIVE FIASMA TREATMENT | Valo Health, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| US-12480096-B2 | Clinical gene signature-based human cell culture model and uses thereof | UNIVERSITE DE STRASBOURG (FR) | 2025-11-25 | — | — | US | claimed |
| WO-2025202864-A1 | ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER | iTeos Belgium SA (BE) | 2025-10-02 | — | — | WO | claimed |
| WO-2025074343-A2 | PRODRUGS OF HUMAN DIHYDROOROTATE DEHYDROGENASE (hDHODH) INHIBITORS | DRUG DISCOVERY AND CLINIC S.R.L. (IT) | 2025-04-10 | — | — | WO | claimed |
| WO-2024163699-A1 | SELECTIVE FIASMA TREATMENT | VALO HEALTH, INC. (US) | 2024-08-08 | — | — | WO | claimed |
| EP-4387735-A2 | ANTIVIRAL DRUGS TARGETING THE N-TERMINAL DOMAIN (NTD) OF THE CORONAVIRUS SPIKE RECEPTOR BINDING DOMAIN (RBD) | SOUTHWEST RESEARCH INSTITUTE (US) | 2024-06-26 | — | — | EP | claimed |
| US-20230321008-A1 | INHIBITORS OF ACID SPHINGOMYELINASE FOR PREVENTING AND TREATING THE COVID-19 DISEASE | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) | 2023-10-12 | — | — | US | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| WO-1989010122-A1 | COMPOSITIONS AND METHODS FOR TREATING CUTANEOUS HYPERPROLIFERATIVE DISORDERS | YALE UNIVERSITY (US) | 1989-11-02 | — | — | WO | claimed |
| US-4873228-A | 2-oxo-4-carboxy-pyrimidines and their use as anti-malaria and anti-cancer agents | THE UNIVERSITY OF MELBOURNE (AU) | 1989-10-10 | — | — | US | claimed |
| EP-0170361-B1 | ANTIATHEROSCLEROTIC AGENTS | KOWA COMPANY, LTD. (JP) | 1989-08-02 | — | — | EP | claimed |
| US-4751298-A | Production of 1-(3-hydroxy-propyl)-1,4-diazepane and 1,4-bis(3,4,5-trimethoxy-benzoyloxy)-propyl-diazepane derivatives thereof | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1988-06-14 | — | — | US | claimed |
| US-4751224-A | FORSKOLIN DERIVATIVES; ANTIAGGLOMERANTS | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 1988-06-14 | — | — | US | claimed |
| EP-0235931-A1 | Antiviral combination | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-09-09 | — | — | EP | claimed |
| EP-0217580-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-04-08 | — | — | EP | claimed |
| EP-0170361-A1 | Antiatherosclerotic agents | KOWA COMPANY, LTD. (JP) | 1986-02-05 | — | — | EP | claimed |
| EP-0167567-A1 | TREATMENT OF METASTASIS | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 1986-01-15 | — | — | EP | claimed |
| WO-1985002616-A1 | TREATMENT OF METASTASIS | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 1985-06-20 | — | — | WO | claimed |